

DRIVE-AB

RE-INVESTMENT
IN R&D AND RESPONSIBLE
ANTIBIOTIC USE

www.drive-ab.eu[@DRIVE_AB](https://twitter.com/DRIVE_AB)

Driving reinvestment in R&D for
antibiotics and advocating their
responsible use

May 2016

PLEASE FORWARD THIS TO ANYONE WHO MAY BE INTERESTED



Don't miss a beat - follow us on Twitter at [@DRIVE_AB](https://twitter.com/DRIVE_AB).

Want to get involved? Just go to our website and click "**Stakeholder Engagement**" to find out all you need to know about getting involved with the project!

What is DRIVE-AB?


DRIVE-AB is a public-private consortium funded by the EU Innovative Medicines Initiative (IMI) and is composed of **16 public and 7 private partners from 12 countries**.

DRIVE-AB is addressing the growing threat of antibiotic resistance. The development of new drugs to treat drug-resistant bacterial infections is moving slowly; we need new economic models that will **stimulate the discovery and development of new antibiotics while ensuring responsible use and access**. This is where DRIVE-AB comes in.

Six teams (work packages) are working together over this three year project (2014-2017), along with the input of a wide variety of stakeholders, to produce these models in a stepwise process and will present them to appropriate decision-makers.

To see an overview of DRIVE-AB **activities and timeline**, [click here](#).

To view the complete DRIVE-AB **information package**, please [click here](#).



DRIVE-AB Conference: Stimulating innovation, sustainable use and global access to antibiotics

2 June 2016

DRIVE-AB is organizing a **high-level conference** to bring together policy makers, regulatory and public health experts and economists to identify and evaluate reward models that are feasible, practical and can be implemented globally. It is expected to stimulate a dialogue among international decision-makers on the implementation of research and development (R&D) incentive policies which will help to inform DRIVE-AB's final recommendations in 2017. **A preliminary programme is available online.** Online registration is now up and running. If you wish to attend, please contact Rob Ewers at Robert Ewers REwers@chathamhouse.org.

Update on DRIVE-AB midterm progress

A poster summarizing DRIVE-AB progress to date was developed for the European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), April 2016 - [click](#) to read an overview of DRIVE-AB's midterm progress.



DRIVE-AB's team "Responsible use of antibiotics, new and old", presented preliminary results at ECCMID 2016 - See the results below!

The team presented their preliminary findings regarding quality and quantity indicators and metrics of antibiotic use in patients in the form of four posters and one oral presentation at ECCMID this year. See their results for yourself here:

1. **Metrics for quantifying antimicrobial use in a hospital setting: results from a systematic review** (poster)
2. **Quantity metrics assessing antibiotic use in the outpatient setting: a global consensus procedure** (poster)
3. **Variation in indicators of antibiotic use among and within different settings: a systematic review** (poster)
4. **Quality indicators assessing antibiotic use in the outpatient setting: a systematic literature review followed by a consensus procedure** (poster)
5. **Quality indicators of antibiotic use in the inpatient setting: a global consensus procedure** (slide set)

What have we been up since our last newsletter?

Since we last checked in with you, DRIVE-AB participants have been busy **engaging with stakeholders and other initiatives from around the world.**

We have been attending and organizing meetings in **London, Tuscany** and with the **International Congress on Infectious Diseases** in Hyderabad, India. We have also held a Train-the-Trainer stakeholder meeting with senior members of the medical antibiotic stewardship community, titled, "Defining and implementing responsible antibiotic use". **Please see the website for more information.**

Please click here for a full list of DRIVE-AB meetings and events.

Project updates by each work package

For a full breakdown of the work packages and their activities, **please check out our website.**

Responsible use of antibiotics, new and old

The team is conducting interviews with partner hospitals. This is part of their study on barriers to responsible antibiotic use in inpatients, and administering a survey on the definition of responsible use, which is scheduled to close at the end of May 2016. The first case study has been finalized and will serve as the format framework for the following three.

To find out more about these activities, or if you would like to provide your valuable feedback as a stakeholder, please see **Work Package 1A's stakeholder engagement page.**

Setting, communicating and revising public health priorities

The team has completed a systematic review to determine the clinical impact of antimicrobial resistance and is finalising a data review of multidrug-resistant organism (MDRO) data. They are also working on progressing their mathematical model of within-hospital spread of MDROs to model global spread. This complex progression is expected to be completed in August 2016, and the final mathematical model is expected to be released in December 2016.

To find out more about these activities, or if you would like to provide your valuable feedback as a stakeholder, please see [Work Package 1B's stakeholder engagement page](#).

Antibiotic Valuation

The group has completed a compilation of a list of 8 case studies including public health priorities and is in the process of developing a set of Health Technology Assessment case studies. Over the next few months, the team will be finalizing a paper providing a framework for valuing antibiotics.

For more detailed information on the group's progress and to find out how you can get involved, please see [Work Package 1C's stakeholder engagement page](#).

Creation and testing of new economic models

The team has completed a report titled, "[Identified risks and bottlenecks to antibiotics innovation](#)". Moving forward, the group plans to continue work on selecting and refining models, designing simulations, evaluating the impact of market transitions on prescribing volumes, and laying the groundwork for the eventual implementation plan. This team will host a stakeholder meeting following the [DRIVE-AB Conference](#) on 3 June 2016 in Amsterdam. At this meeting, the group will share DRIVE-AB's preliminary technical analysis of their most promising reward models, identify implementation challenges and knowledge gaps and develop a roadmap for the remaining 18 months of the project.

For more detailed information on the group's progress and to find out how you can get involved, please see [Work Package 2's stakeholder engagement page](#).

Project management and governance

Along with ongoing project monitoring and management activities, the team has been supporting WP3B in the planning of the DRIVE-AB conference in June and has been holding monthly scientific forums for DRIVE-AB participants. The group has also had significant success in increasing industry involvement in the project. In late May 2016, WP3A will organise with IMI the midterm project review meeting (an internal process within IMI during which the progress of the project is evaluated by external experts).

For more detailed information on the group's progress, please see the [DRIVE-AB website](#).

Stakeholder platform and external communication

In addition to the development of the [poster at ECCMID](#) and the [policy brief](#), the team have been very busy planning and organizing the DRIVE-AB conference for policy-makers which will be held in Amsterdam on 2 June 2016. They also facilitated Work Package 1A's [Train-the-Trainer event](#) on defining and implementing responsible use in Europe. In addition to organising meetings, the group continues to manage project communications both internally and externally by monitoring and updating the website, the Twitter account and the newsletters, planning other upcoming meetings, and managing potential and novel stakeholders.

For more detailed information on the group's progress, please see the [DRIVE-AB website](#).

Want to find out more?

Should you wish to receive more detailed information, subscribe to the newsletter, nominate a stakeholder or update us on your activities as relevant to the project, please contact [Victoria Wells](#), DRIVE-AB Communications Officer.

[Edit your subscription](#) | [Unsubscribe](#)